A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Hunter Syndrome Clinical Trial

Official title:

An Open-label, Multicenter, Phase 4 Study to Assess the Effects of a Prophylactic Immune Tolerizing Regimen in MPS II Treatment-Naïve Patients Planned to Receive ELAPRASE Who Are at Risk of Developing Persistent Neutralizing Antibodies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05494593
• Other study ID #: TAK-665-4003
• Status: Recruiting
• Phase: Phase 4
• Start date: February 28, 2023
• Est. completion date: June 15, 2027

Study information

• Verified date: September 2023
• Source: Takeda
• Contact: Takeda Contact
• Phone: +1-877-825-3327
• Email: medinfoUS[@]takeda.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main aim of this study is to evaluate the ability of a prophylactic immune tolerizing regimen (ITR) to prevent or reduce the development of high titer anti-idursulfase antibodies in treatment-naïve participants with Hunter syndrome.

In this open label, single arm study, all participants will receive ELAPRASE treatment and a prophylactic ITR.

Participants will be treated with ELAPRASE for up to 104 weeks. The prophylactic ITR will start 1 day prior to the start of ELAPRASE. The prophylactic ITR will consist of a 5-week cycle of: Rituximab (intravenously [IV], weekly for 4 weeks); Methotrexate (oral, 3 times per week for 5 weeks) and intravenous immunoglobulin (IVIG) (IV, every 4 weeks of the cycle).

Following the completion of 1 cycle, an assessment will be made at Month 6, 12, and 18 regarding the need for administering another 5-week cycle of the ITR.

Participants will be in the study for approximately 112 weeks (including 6 weeks for screening, up to 104 weeks for treatment, and 2 weeks for follow-up).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5
• Est. completion date: June 15, 2027
• Est. primary completion date: June 15, 2027
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A to 6 Years

Eligibility

Inclusion Criteria:

• Participant is male.

• Participant is ELAPRASE-naïve at study entry.

• Participant must have a documented diagnosis of MPS II. The following combination will be accepted as diagnostic of MPS II:

• Participant has a deficiency in iduronate-2-sulfatase (I2S) enzyme activity of less than or equal to (<=) 10 percent (%) of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on the reference laboratory's normal range). The participant has a normal enzyme activity level of at least 1 other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on the reference laboratory's normal range).

• Participant has a documented mutation in the IDS gene; additionally, participants must have a severe mutation (example, large deletion or complex gene rearrangement), which is predicted to lead to development of a persistent anti-idursulfase antibody response.

• Participant will be less than (<) 6 years of age at enrollment.

• Participant has a negative test result for serum anti-idursulfase antibodies.

Exclusion Criteria:

• Participant has received treatment with any investigational drug within the 30 days prior to study entry.

• Participant has received or is receiving treatment with idursulfase-IT.

• Participant has received growth hormones, a cord blood infusion, or a bone marrow transplant at any time.

• Participant has received blood product transfusions within 90 days prior to screening.

• Participant is unable to comply with the protocol as determined by the investigator.

• Participant has known or suspected intolerance or hypersensitivity to the investigational product(s), closely related compounds, or any of the stated ingredients, including the prophylactic ITR.

• Participant has current or recurrent disease that could affect the action, absorption, or disposition of the investigational product, or clinical or laboratory assessments.

• Participant has current or relevant history of physical or psychiatric illness, or any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures.

• Participant has current use of any medication (including over-the-counter, herbal, or homeopathic preparations) that could affect (improve or worsen) the condition being studied, or could affect the action, absorption, or disposition of the investigational product(s), or clinical or laboratory assessment (Current use is defined as use within 30 days).

• Within 30 days prior to the first dose of investigational product, the participant has been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this study.

Related Conditions & MeSH terms

• Hunter Syndrome
• Mucopolysaccharidoses
• Mucopolysaccharidosis (MPS)
• Mucopolysaccharidosis II
• Syndrome

Intervention

Drug:
• ELAPRASE
Participants will receive 0.5 milligram per kilogram (mg/kg) of body weight of ELAPRASE, intravenous, infusion for 104 weeks.
• Rituximab
Participants will receive 375 milligram per square meter per dose (mg/m^2/dose) of intravenous rituximab weekly for 4 weeks in 5-week cycle.
• Methotrexate
Participants will receive 0.4 mg/kg of methotrexate by mouth (PO) 3 times per week for 5 weeks in each cycle.
• Intravenous Immunoglobulin (IVIG)
Participants will receive 500 mg/kg of IVIG every 4 weeks in 5-week cycle.

Locations

Country	Name	City	State
United States	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina
United States	Ann and Robert H Lurie Childrens Hospital of Chicago	Chicago	Illinois
United States	Children's Hospitals and Clinics of Minnesota	Minneapolis	Minnesota
United States	NewYork-Presbyterian Morgan Stanley Children's Hospital	New York	New York
United States	Children's Hospital and Research Center at Oakland	Oakland	California
United States	Phoenix Childrens Hospital	Phoenix	Arizona
United States	Children's Hospital of Pittsburgh	Pittsburgh	Pennsylvania
United States	UC Davis Medical Center	Sacramento	California
United States	Rady Childrens Hospital San Diego - PIN	San Diego	California
United States	The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center	Torrance	California
United States	The Cleveland Clinic Foundation	Twinsburg	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Takeda	Takeda Development Center Americas, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Anti-Idursulfase Antibodies Formation, Including Anti-Idursulfase Antibodies That Have Enzyme Neutralizing Activity	Serum samples will be collected for evaluation of anti-idursulfase antibodies including binding antibodies and neutralizing antibodies. Analysis of anti-idursulfase antibodies will be conducted using validated 3-tier immunoassay methods. Rate will be defined as the number of participants having positive antibodies compared to the total number of participants.	Up to 24 months
Secondary	Correlation Between Anti-drug Antibody (ADA) Responses and Iduronate-2-Sulfatase (IDS) Gene Mutations and Clinical Outcomes	Correlation between ADA responses and IDS gene mutations and clinical outcomes (efficacy and safety) every 6 months in comparison to historical results from Study SHPELA- 401 (NCT02455622) without immune tolerance treatment will be reported. Analysis of covariance will be performed to correlate ADA response, IDS gene mutation and clinical outcomes.	Every 6 months up to 24 months
Secondary	Change From Baseline in Urinary Glycosaminoglycan (uGAG) Levels Normalized to Urine Creatinine	Urine samples will be collected for the determination of uGAG levels and urine creatinine monthly prior to dosing. Change from baseline in uGAG levels normalized to urine creatinine will be reported.	Up to 24 months
Secondary	Change From Baseline in Normalized uGAG per Upper Limit of Normal for age (uGAG)/ULN)	Urine samples will be collected for the determination of uGAG levels monthly prior to dosing. Change from baseline in normalized uGAG/ULN will be reported.	Up to 24 months
Secondary	Change From Baseline in Liver Volume	Liver volume will be measured using abdominal ultrasonography. Change from baseline values for liver volume will be reported.	Up to 24 months

External Links

•   To obtain more information on the study, click here/on this link